Status:

UNKNOWN

A Trial to Evaluate the Combination Efficacy of Artificial Dermis and Growth Factor in Chronic Wounds Ulcer

Lead Sponsor:

Second Affiliated Hospital, School of Medicine, Zhejiang University

Conditions:

Chronic Wound

Eligibility:

All Genders

Phase:

NA

Brief Summary

Double layer artificial dermis repair material has been widely used in scar plastic, burn, trauma, chronic wounds and other aspects of wound repair and reconstruction. In the course of clinical applic...

Eligibility Criteria

Inclusion

  • Patients diagnosed as chronic wounds ulcer;
  • The affected limb has sufficient blood perfusion. The ankle brachial index was 0.65-1.3, or the partial pressure of oxygen was more than 40 mmHg, or Doppler ultrasound showed enough blood flow.
  • After debridement, the distance between the wound and the edge of other ulcers was \>2cm.
  • After debridement, the area of exposed bone or tendon was \>4cm2.
  • The wound was completely debridement without obvious necrosis, infection control or osteomyelitis control.
  • The duration of ulcer wound was at least 30 days.
  • Sign the informed consent voluntarily.

Exclusion

  • Poor control of diabetes (fasting blood glucose ≥ 8.0mmol/l, HbA1c ≥ 12%);
  • The researchers think that there are factors affecting wound healing, such as the use of corticosteroids, immunosuppressants and other drugs, chemotherapy or radiotherapy within one year.
  • To receive or plan to receive drugs or treatment, the researchers believe that these drugs or treatment will interfere with or affect the speed and quality of wound healing;
  • Unstable Charcot's foot or Charcot's joint disease with bone protrusion;
  • Patients with severe lymphedema, coagulation disorders, autoimmune diseases, cardiovascular and cerebrovascular diseases, and severe hepatopulmonary and renal diseases;
  • Those who have received hyperbaric oxygen treatment within 5 days before enrollment, or who have received or plan to receive growth factor, tissue-engineered skin or other skin substitutes treatment within 30 days;
  • Those who have participated in or are participating in other clinical studies within 30 days before screening;
  • Pregnant, or lactating women;
  • Poor general condition or other conditions not suitable for the use of double-layer artificial leather repair materials;
  • Be allergic to collagen or chondroitin sulfate;
  • Other cases that researchers think are not suitable for the participation.

Key Trial Info

Start Date :

March 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 30 2022

Estimated Enrollment :

64 Patients enrolled

Trial Details

Trial ID

NCT04132635

Start Date

March 1 2020

End Date

June 30 2022

Last Update

October 21 2019

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.